Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling.


Journal

Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571

Informations de publication

Date de publication:
19 12 2019
Historique:
received: 08 10 2018
revised: 22 07 2019
accepted: 05 09 2019
pubmed: 14 10 2019
medline: 20 2 2020
entrez: 14 10 2019
Statut: ppublish

Résumé

The Ras GTPases are frequently mutated in human cancer, and, although the Raf kinases are essential effectors of Ras signaling, the tumorigenic properties of specific Ras-Raf complexes are not well characterized. Here, we examine the ability of individual Ras and Raf proteins to interact in live cells using bioluminescence resonance energy transfer (BRET) technology. We find that C-Raf binds all mutant Ras proteins with high affinity, whereas B-Raf exhibits a striking preference for mutant K-Ras. This selectivity is mediated by the acidic, N-terminal segment of B-Raf and requires the K-Ras polybasic region for high-affinity binding. In addition, we find that C-Raf is critical for mutant H-Ras-driven signaling and that events stabilizing B-Raf/C-Raf dimerization, such as Raf inhibitor treatment or certain B-Raf mutations, can allow mutant H-Ras to engage B-Raf with increased affinity to promote tumorigenesis, thus revealing a previously unappreciated role for C-Raf in potentiating B-Raf function.

Identifiants

pubmed: 31606273
pii: S1097-2765(19)30689-6
doi: 10.1016/j.molcel.2019.09.004
pmc: PMC7001861
mid: NIHMS1540003
pii:
doi:

Substances chimiques

KRAS protein, human 0
BRAF protein, human EC 2.7.11.1
Braf protein, mouse EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1
Proto-Oncogene Proteins c-raf EC 2.7.11.1
Raf1 protein, human EC 2.7.11.1
Raf1 protein, mouse EC 2.7.11.1
raf Kinases EC 2.7.11.1
HRAS protein, human EC 3.6.5.2
Hras protein, mouse EC 3.6.5.2
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2
ras Proteins EC 3.6.5.2

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

872-884.e5

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM124233
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC010329-19
Pays : United States
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC010329
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

Nat Rev Cancer. 2011 Oct 13;11(11):761-74
pubmed: 21993244
J Immunol Methods. 2009 Aug 15;347(1-2):70-8
pubmed: 19567251
Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):5982-6
pubmed: 8016101
J Biol Chem. 2000 Feb 11;275(6):3737-40
pubmed: 10660519
Mol Cell. 2005 Jan 21;17(2):215-24
pubmed: 15664191
J Biol Chem. 2007 Sep 7;282(36):26503-16
pubmed: 17635919
Small GTPases. 2010 Jul;1(1):2-27
pubmed: 21686117
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Nat Rev Cancer. 2007 Apr;7(4):295-308
pubmed: 17384584
Cell. 2018 Feb 8;172(4):857-868.e15
pubmed: 29336889
Mol Cell Biol. 2010 Feb;30(3):806-19
pubmed: 19933846
J Biol Chem. 2002 Jul 5;277(27):24090-102
pubmed: 11953426
Nat Rev Mol Cell Biol. 2015 May;16(5):281-98
pubmed: 25907612
Cancer Res. 2016 Mar 15;76(6):1476-84
pubmed: 26825172
Mol Cancer Res. 2015 Sep;13(9):1325-35
pubmed: 26037647
Small GTPases. 2019 May 7;:1-12
pubmed: 31062644
Cell. 2017 Jan 12;168(1-2):239-251.e16
pubmed: 28041850
Nat Methods. 2006 Mar;3(3):165-74
pubmed: 16489332
Cell. 2013 Aug 29;154(5):1036-1046
pubmed: 23993095
Sci Signal. 2017 Sep 26;10(498):
pubmed: 28951536
Nature. 2015 Oct 22;526(7574):583-6
pubmed: 26466569
J Biol Chem. 2011 Feb 4;286(5):3323-31
pubmed: 21098031
Mol Cancer Res. 2015 Apr;13(4):595-603
pubmed: 25566993
Br J Cancer. 2018 Jan;118(1):3-8
pubmed: 29235562
Cancer Res. 2012 May 15;72(10):2457-67
pubmed: 22589270
J Clin Oncol. 2012 Jan 20;30(3):316-21
pubmed: 22067401
Genes Cancer. 2011 Mar;2(3):344-58
pubmed: 21779504
J Biol Chem. 2000 Jul 21;275(29):22172-9
pubmed: 10777480
Cell. 2017 Jun 29;170(1):17-33
pubmed: 28666118
Cell. 2007 Jun 1;129(5):865-77
pubmed: 17540168
N Engl J Med. 2012 Jan 19;366(3):207-15
pubmed: 22256804
Mol Cell. 2013 Feb 21;49(4):751-8
pubmed: 23352452
Semin Cell Dev Biol. 2012 Apr;23(2):145-53
pubmed: 21924373
EMBO J. 2010 Mar 17;29(6):1091-104
pubmed: 20150892
Nature. 2017 Aug 10;548(7666):234-238
pubmed: 28783719
Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18519-24
pubmed: 24158481

Auteurs

Elizabeth M Terrell (EM)

Laboratory of Cell and Developmental Signaling, NCI-Frederick, Frederick, MD 21702, USA.

David E Durrant (DE)

Laboratory of Cell and Developmental Signaling, NCI-Frederick, Frederick, MD 21702, USA.

Daniel A Ritt (DA)

Laboratory of Cell and Developmental Signaling, NCI-Frederick, Frederick, MD 21702, USA.

Nancy E Sealover (NE)

Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.

Erin Sheffels (E)

Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.

Russell Spencer-Smith (R)

Laboratory of Cell and Developmental Signaling, NCI-Frederick, Frederick, MD 21702, USA.

Dominic Esposito (D)

NCI-Ras Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, MD 21702, USA.

Yong Zhou (Y)

Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.

John F Hancock (JF)

Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.

Robert L Kortum (RL)

Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.

Deborah K Morrison (DK)

Laboratory of Cell and Developmental Signaling, NCI-Frederick, Frederick, MD 21702, USA. Electronic address: morrisod@mail.nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH